menu search

Y-mabs announces complete response letter for omburtamab biologics license application

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharma...

December 1, 2022, 10:34 pm

Fda pulls covid antibody treatment because it's not effective against dominant omicron variants

The FDA said bebtelovimab is no longer authorized for use because it is not expected to neutralize the omicron BQ.1 and BQ.1.1 subvariants....

December 1, 2022, 4:32 pm

Hillstream biopharma announces development of proprietary targeted biologics, knob quatrabodies™ (hsb-1940) against pd-1, by combining quatramers™ with omniab’s picobodies™, via a collaboration agreem

Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor target...

December 1, 2022, 1:47 pm

Biogen (biib) down on report of death in alzheimer's study

Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) ...

November 29, 2022, 2:18 pm

Context therapeutics finds lead clinical development candidate for cancer treatment in ctim-76

Context Therapeutics (NASDAQ:CNTX) Inc has designated CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to ta...

November 29, 2022, 10:52 am

Tiziana life sciences publishes peer-reviewed research, showing intranasal administered drug for autoimmune diseases is safe in humans

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has published a scientific article in the peer-reviewed journal Frontiers in Immunology, showing a fav...

November 23, 2022, 11:41 am

Tracon pharmaceuticals doses first patient in drug trial to treat malignant tumours

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has dosed the first patient in a Phase 1/2 trial evaluating the company's CTLA-4 antibody, YH001, in...

November 21, 2022, 8:41 am

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm

Eisai to present full findings from lecanemab confirmatory phase 3 clinical trial (clarity ad) and other alzheimer's disease research at the 15th clinical trials on alzheimer's disease (ctad) conferen

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker...

November 20, 2022, 6:30 pm


Search within

Pages Search Results: